Cargando…
Optimal long-term antithrombotic management of atrial fibrillation: life cycle management
Optimal antithrombotic management of atrial fibrillation equals balancing between prevention of arterial thromboembolism, predominantly ischaemic stroke, and haemorrhagic complications. Over time different antithrombotic agents and strategies have been developed. At present, non-vitamin K antagonist...
Autores principales: | Pisters, R., Elvan, A., Crijns, H. J. G. M., Hemels, M. E. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968005/ https://www.ncbi.nlm.nih.gov/pubmed/29722003 http://dx.doi.org/10.1007/s12471-018-1118-0 |
Ejemplares similares
-
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry
por: Pisters, R., et al.
Publicado: (2017) -
Low efficacy of cardioversion of persistent atrial fibrillation with the implantable cardioverter-defibrillator
por: Limantoro, I., et al.
Publicado: (2013) -
Prognostic significance of incident atrial fibrillation following STEMI depends on the timing of atrial fibrillation
por: Gal, P., et al.
Publicado: (2015) -
Effective contact and outcome after pulmonary vein isolation in novel circular multi-electrode atrial fibrillation ablation
por: Gal, P., et al.
Publicado: (2016) -
Antithrombotic management of patients with atrial fibrillation—Dutch anticoagulant initiatives anno 2020
por: Chu, G., et al.
Publicado: (2020)